Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing Sarcoma to Be Presented at the CTOS 2019 Annual Meeting
Oncternal Therapeutics, Inc. (ONCT)
Last oncternal therapeutics, inc. earnings: 8/8 04:01 pm
Check Earnings Report
Company Research
Source: Business Wire
SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim data on TK216 – an investigational targeted small molecule inhibitor of ETS transcription factor oncoproteins – will be presented at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting in Tokyo, Japan, on November 16, 2019. The oral presentation (abstract 3250355) titled “A Phase 1 Dose Escalation Study of Intravenous TK216 in Patients with Relapsed or Refractory Ewing Sarcoma” will be given by Paul A. Meyers, M.D., Chief, Pediatric Sarcoma Service and Vice Chair for Clinical Affairs of Memorial Sloan Kettering Cancer Center.About TK216TK216 is an investigational, potentially first-in-class small molecule that is designed to inhibit the biological activity of E26 transformation-specific (ETS) transcription factor oncoproteins, including fusion proteins. Tumorigenic gene
Show less
Read more
Impact Snapshot
Event Time:
ONCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCT alerts
High impacting Oncternal Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ONCT
News
- Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerGlobeNewswire
ONCT
Earnings
- 8/8/24 - Beat
ONCT
Analyst Actions
- 9/12/24 - Northland Securities
ONCT
Sec Filings
- 11/14/24 - Form 8-K
- 11/6/24 - Form 10-Q
- 10/15/24 - Form 144
- ONCT's page on the SEC website